{"id":45138,"date":"2025-10-29T14:01:45","date_gmt":"2025-10-29T06:01:45","guid":{"rendered":"https:\/\/flcube.com\/?p=45138"},"modified":"2025-10-29T14:01:46","modified_gmt":"2025-10-29T06:01:46","slug":"junshi-biosciences-q3-2025-revenue-climbs-31-toripalimab-drives-growth-nmpa-approves-snda","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45138","title":{"rendered":"Junshi Biosciences Q3\u202f2025 Revenue Climbs 31%, Toripalimab Drives Growth, NMPA Approves sNDA"},"content":{"rendered":"\n<p>Shanghai Junshi Biosciences Co.,\u202fLtd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/1877:HKG\">HKG: 1877<\/a>, \u202f<a href=\"https:\/\/www.google.com\/finance\/quote\/688180:SHA\">SHA: 688180<\/a>) today released its third\u2011quarter 2025 financial results. Operating revenue rose <strong>RMB\u202f637\u202fmillion<\/strong>, a <strong>31.4\u202f% year\u2011on\u2011year increase<\/strong>. For the first nine months of 2025, total revenue reached <strong>RMB\u202f1.806\u202fbillion<\/strong>, up <strong>42.06\u202f%<\/strong> YoY.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-highlights\"><strong>Highlights<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q3\u202f2025<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td>Operating Revenue<\/td><td>RMB\u202f637\u202fmillion<\/td><td>+31.4\u202f%<\/td><\/tr><tr><td>9\u2011Month Revenue<\/td><td>RMB\u202f1.806\u202fbillion<\/td><td>+42.06\u202f%<\/td><\/tr><tr><td>Cash &amp; Cash\u2011Equivalents (End\u2011of\u2011Period)<\/td><td>RMB\u202f3.270\u202fbillion<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-revenue-drivers\"><strong>Revenue Drivers<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Toripalimab (LOQTORZI, JS001)<\/strong> sold <strong>\u2248\u202fRMB\u202f1.495\u202fbillion<\/strong> in the domestic Chinese market, up <strong>~40\u202f% YoY<\/strong>.<\/li>\n\n\n\n<li>Net loss narrowed significantly versus the same period in 2024.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-regulatory-milestones\"><strong>Regulatory Milestones<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NMPA<\/strong> accepted a supplemental New Drug Application (sNDA) for toripalimab as first\u2011line therapy in HER2\u2011expressing urothelial carcinoma.<\/li>\n\n\n\n<li>12 indications approved in mainland China; 10 listed on China\u2019s National Reimbursement Drug List (NRDL).<\/li>\n\n\n\n<li>Toripalimab approved in <strong>>\u202f40<\/strong> countries\/regions (incl. U.S., EU, India, U.K., Australia, Canada, UAE, etc.) and is under review in multiple other markets.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pipeline-amp-clinical-development\"><strong>Pipeline &amp; Clinical Development<\/strong><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Development Stage<\/th><th>Target Indication<\/th><th>Regulatory Status<\/th><\/tr><\/thead><tbody><tr><td><strong>JS207<\/strong> (PD\u20111\/VEGF bispecific)<\/td><td>Phase\u202fII\/III<\/td><td>Neoadjuvant NSCLC<\/td><td>FDA IND approved<\/td><\/tr><tr><td><strong>JS005<\/strong> (Anti\u2011IL\u201117A mAb)<\/td><td>Phase\u202fIII<\/td><td>Moderate\u2011to\u2011severe plaque psoriasis<\/td><td>Primary endpoint met<\/td><\/tr><tr><td><strong>JT118<\/strong> (Monkeypox vaccine)<\/td><td>Phase\u202fI\/II<\/td><td>Monkeypox<\/td><td>NMPA CTA approved<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025102802225_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025102802225_c.\"><\/object><a id=\"wp-block-file--media-9d0e18b4-7e3d-4932-891b-12bc4dd155e1\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025102802225_c.pdf\">2025102802225_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025102802225_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9d0e18b4-7e3d-4932-891b-12bc4dd155e1\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Junshi Biosciences Co.,\u202fLtd. (HKG: 1877, \u202fSHA: 688180) today released its third\u2011quarter 2025 financial results&#8230;.<\/p>\n","protected":false},"author":1,"featured_media":45144,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,899,296,900],"class_list":["post-45138","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-hkg-1877","tag-junshi-biosciences","tag-sha-688180"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Junshi Biosciences Q3\u202f2025 Revenue Climbs 31%, Toripalimab Drives Growth, NMPA Approves sNDA - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Junshi Biosciences Co.,\u202fLtd. (HKG: 1877, \u202fSHA: 688180) today released its third\u2011quarter 2025 financial results. Operating revenue rose RMB\u202f637\u202fmillion, a 31.4\u202f% year\u2011on\u2011year increase. For the first nine months of 2025, total revenue reached RMB\u202f1.806\u202fbillion, up 42.06\u202f% YoY.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45138\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Q3\u202f2025 Revenue Climbs 31%, Toripalimab Drives Growth, NMPA Approves sNDA\" \/>\n<meta property=\"og:description\" content=\"Shanghai Junshi Biosciences Co.,\u202fLtd. (HKG: 1877, \u202fSHA: 688180) today released its third\u2011quarter 2025 financial results. Operating revenue rose RMB\u202f637\u202fmillion, a 31.4\u202f% year\u2011on\u2011year increase. For the first nine months of 2025, total revenue reached RMB\u202f1.806\u202fbillion, up 42.06\u202f% YoY.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45138\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-29T06:01:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-29T06:01:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2903.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45138#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45138\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Junshi Biosciences Q3\u202f2025 Revenue Climbs 31%, Toripalimab Drives Growth, NMPA Approves sNDA\",\"datePublished\":\"2025-10-29T06:01:45+00:00\",\"dateModified\":\"2025-10-29T06:01:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45138\"},\"wordCount\":226,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45138#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2903.webp\",\"keywords\":[\"Finanical Reports\",\"HKG: 1877\",\"Junshi Biosciences\",\"SHA: 688180\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45138#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45138\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45138\",\"name\":\"Junshi Biosciences Q3\u202f2025 Revenue Climbs 31%, Toripalimab Drives Growth, NMPA Approves sNDA - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45138#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45138#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2903.webp\",\"datePublished\":\"2025-10-29T06:01:45+00:00\",\"dateModified\":\"2025-10-29T06:01:46+00:00\",\"description\":\"Shanghai Junshi Biosciences Co.,\u202fLtd. (HKG: 1877, \u202fSHA: 688180) today released its third\u2011quarter 2025 financial results. Operating revenue rose RMB\u202f637\u202fmillion, a 31.4\u202f% year\u2011on\u2011year increase. For the first nine months of 2025, total revenue reached RMB\u202f1.806\u202fbillion, up 42.06\u202f% YoY.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45138#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45138\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45138#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2903.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2903.webp\",\"width\":1080,\"height\":608,\"caption\":\"Junshi Biosciences Q3\u202f2025 Revenue Climbs 31%, Toripalimab Drives Growth, NMPA Approves sNDA\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45138#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Junshi Biosciences Q3\u202f2025 Revenue Climbs 31%, Toripalimab Drives Growth, NMPA Approves sNDA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Q3\u202f2025 Revenue Climbs 31%, Toripalimab Drives Growth, NMPA Approves sNDA - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Junshi Biosciences Co.,\u202fLtd. (HKG: 1877, \u202fSHA: 688180) today released its third\u2011quarter 2025 financial results. Operating revenue rose RMB\u202f637\u202fmillion, a 31.4\u202f% year\u2011on\u2011year increase. For the first nine months of 2025, total revenue reached RMB\u202f1.806\u202fbillion, up 42.06\u202f% YoY.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45138","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Q3\u202f2025 Revenue Climbs 31%, Toripalimab Drives Growth, NMPA Approves sNDA","og_description":"Shanghai Junshi Biosciences Co.,\u202fLtd. (HKG: 1877, \u202fSHA: 688180) today released its third\u2011quarter 2025 financial results. Operating revenue rose RMB\u202f637\u202fmillion, a 31.4\u202f% year\u2011on\u2011year increase. For the first nine months of 2025, total revenue reached RMB\u202f1.806\u202fbillion, up 42.06\u202f% YoY.","og_url":"https:\/\/flcube.com\/?p=45138","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-29T06:01:45+00:00","article_modified_time":"2025-10-29T06:01:46+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2903.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45138#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45138"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Junshi Biosciences Q3\u202f2025 Revenue Climbs 31%, Toripalimab Drives Growth, NMPA Approves sNDA","datePublished":"2025-10-29T06:01:45+00:00","dateModified":"2025-10-29T06:01:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45138"},"wordCount":226,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45138#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2903.webp","keywords":["Finanical Reports","HKG: 1877","Junshi Biosciences","SHA: 688180"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45138#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45138","url":"https:\/\/flcube.com\/?p=45138","name":"Junshi Biosciences Q3\u202f2025 Revenue Climbs 31%, Toripalimab Drives Growth, NMPA Approves sNDA - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45138#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45138#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2903.webp","datePublished":"2025-10-29T06:01:45+00:00","dateModified":"2025-10-29T06:01:46+00:00","description":"Shanghai Junshi Biosciences Co.,\u202fLtd. (HKG: 1877, \u202fSHA: 688180) today released its third\u2011quarter 2025 financial results. Operating revenue rose RMB\u202f637\u202fmillion, a 31.4\u202f% year\u2011on\u2011year increase. For the first nine months of 2025, total revenue reached RMB\u202f1.806\u202fbillion, up 42.06\u202f% YoY.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45138#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45138"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45138#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2903.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2903.webp","width":1080,"height":608,"caption":"Junshi Biosciences Q3\u202f2025 Revenue Climbs 31%, Toripalimab Drives Growth, NMPA Approves sNDA"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45138#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Junshi Biosciences Q3\u202f2025 Revenue Climbs 31%, Toripalimab Drives Growth, NMPA Approves sNDA"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2903.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45138"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45138\/revisions"}],"predecessor-version":[{"id":45145,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45138\/revisions\/45145"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45144"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}